Royalty Financial Statements From 2010 to 2026

Stocks USA . 
Stock . Royalty Pharma Plc
RPRX Stock  USD 46.21  0.85  1.87%   
Royalty Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Royalty Pharma's valuation are provided below:
Gross Profit
2.7 B
Profit Margin
0.3242
Market Capitalization
26.7 B
Enterprise Value Revenue
11.3096
Revenue
2.4 B
We have found one hundred twenty available trending fundamental ratios for Royalty Pharma Plc, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Royalty Pharma Plc recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to drop to about 16.9 B in 2026

Royalty Pharma Total Revenue

1.3 Billion

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 323 M, Total Revenue of 1.3 B or Research Development of 474.6 M, as well as many indicators such as Price To Sales Ratio of 9.96, Dividend Yield of 0.035 or PTB Ratio of 3.76. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Build AI portfolio with Royalty Stock
Check out the analysis of Royalty Pharma Correlation against competitors.

Royalty Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets20.6 B19.6 B11 B
Slightly volatile
Other Current Liabilities248.6 M236.8 M129.1 M
Slightly volatile
Total Current Liabilities668 M636.2 M370 M
Slightly volatile
Total Stockholder Equity6.8 B6.5 B4.3 B
Slightly volatile
Other Liabilities2.4 M2.2 M2.6 M
Slightly volatile
Accounts Payable20.4 M19.4 M7.6 M
Slightly volatile
Cash568.9 M618.7 M820.9 M
Slightly volatile
Common Stock Shares Outstanding447.4 M559.6 M440 M
Slightly volatile
Short Term Investments17.9 M18.8 M521.4 M
Pretty Stable
Inventory1.091.1586.6 M
Very volatile
Total Liabilities10.4 B9.9 B5.1 B
Slightly volatile
Common Stock100.7 K106 K579.3 M
Very volatile
Property Plant Equipment2.6 K2.7 K45.4 K
Slightly volatile
Intangible Assets18.3 B17.4 B3.8 B
Slightly volatile
Net Tangible Assets3.7 B6.5 B3.1 B
Slightly volatile
Total Current Assets588 M619 M1.5 B
Slightly volatile
Short and Long Term Debt Total8.1 B9 B7 B
Slightly volatile
Net Debt6.1 B8.3 B5.2 B
Slightly volatile
Non Current Assets Total13.5 B17.1 B11 B
Slightly volatile
Cash And Short Term Investments605.6 M637.5 M1.6 B
Pretty Stable
Liabilities And Stockholders Equity16.6 B19.6 B13.9 B
Slightly volatile
Non Current Liabilities Total7.1 B9.3 B6.3 B
Slightly volatile
Short Term Debt361 M380 M766.5 M
Slightly volatile
Long Term Debt7.2 B8.6 B6.5 B
Slightly volatile
Net Receivables927.9 M883.7 M225.4 M
Slightly volatile
Common Stock Total Equity91.5 K96.3 K1.9 B
Slightly volatile
Long Term Debt Total6.9 B7 B6.3 B
Slightly volatile
Net Invested Capital14.1 B15.4 B12 B
Slightly volatile
Long Term Investments15.1 B17.1 B11.5 B
Slightly volatile
Short and Long Term Debt646.5 M380 M519.4 M
Slightly volatile
Capital Stock100.7 K106 K1.9 B
Slightly volatile
Net Working Capital1.2 B891.9 M1.7 B
Slightly volatile
Current Deferred Revenue24.8 M27.9 M30.5 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity3.6 B3.5 B4.7 B
Slightly volatile
Retained Earnings Total Equity2.3 B2.3 B2 B
Slightly volatile
Capital Surpluse3.7 B4.2 B3.2 B
Slightly volatile
Non Current Liabilities Other126.9 M120.8 M17.2 M
Slightly volatile

Royalty Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Research Development474.6 M452 M132 M
Slightly volatile
Selling General Administrative602.2 M573.5 M157.5 M
Slightly volatile
Depreciation And Amortization3.7 M3.9 M112.1 M
Pretty Stable
EBITDA1.7 B1.6 B1.4 B
Slightly volatile
Interest Income44.9 M33.6 M27 M
Slightly volatile
Non Recurring1.2 B1.4 B1.5 B
Slightly volatile

Royalty Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow923.9 M618.7 M1.3 B
Slightly volatile
Free Cash Flow2.9 B2.5 B2.1 B
Slightly volatile
Begin Period Cash Flow968.2 M929 M1.4 B
Slightly volatile
Other Non Cash Items1.2 B889 M1.5 B
Pretty Stable
Stock Based Compensation304.4 M289.9 M39 M
Slightly volatile
Cash And Cash Equivalents Changes145.1 M152.7 M572.2 M
Slightly volatile
Cash Flows Other Operating2.2 B2.4 B2 B
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.967.017111.2505
Slightly volatile
Dividend Yield0.0350.02270.0381
Slightly volatile
PTB Ratio3.762.57664.131
Slightly volatile
Days Sales Outstanding14213640.0459
Pretty Stable
Book Value Per Share14.4122.494214.7742
Slightly volatile
Free Cash Flow Yield0.110.14920.1188
Slightly volatile
Operating Cash Flow Per Share4.175.7654.6549
Slightly volatile
Stock Based Compensation To Revenue0.130.12190.0167
Slightly volatile
PB Ratio3.762.57664.131
Slightly volatile
EV To Sales12.9610.520713.9545
Slightly volatile
Free Cash Flow Per Share4.175.7654.6549
Slightly volatile
ROIC0.10.08950.0876
Pretty Stable
Net Income Per Share2.621.78511.9757
Slightly volatile
Sales General And Administrative To Revenue0.250.24110.0937
Slightly volatile
Research And Ddevelopement To Revenue0.20.19010.0786
Slightly volatile
Cash Per Share1.41.47613.6103
Pretty Stable
POCF Ratio8.696.70259.2714
Slightly volatile
Interest Coverage4.665.06895.0903
Slightly volatile
Payout Ratio0.470.49060.9489
Pretty Stable
PFCF Ratio8.696.70259.2714
Slightly volatile
Income Quality1.841.88031.7582
Slightly volatile
ROE0.20.1190.1629
Very volatile
EV To Operating Cash Flow11.8110.04912.5313
Slightly volatile
PE Ratio20.5621.646351.4643
Very volatile
Return On Tangible Assets0.03920.04120.1118
Slightly volatile
EV To Free Cash Flow11.8110.04912.5313
Slightly volatile
Earnings Yield0.04780.04620.0478
Slightly volatile
Intangibles To Total Assets0.04480.04710.3802
Slightly volatile
Net Debt To EBITDA3.535.0944.5163
Very volatile
Current Ratio0.920.97297.1681
Slightly volatile
Receivables Turnover2.562.691227.7223
Slightly volatile
Graham Number19.8724.542421.0305
Slightly volatile
Shareholders Equity Per Share10.3214.996711.2189
Slightly volatile
Debt To Equity1.381.3821.2651
Pretty Stable
Revenue Per Share3.825.50654.1109
Slightly volatile
Interest Debt Per Share13.1321.437514.402
Slightly volatile
Debt To Assets0.530.45620.5016
Slightly volatile
Enterprise Value Over EBITDA21.615.296324.6463
Slightly volatile
Short Term Coverage Ratios5.176.55224.4572
Slightly volatile
Price Earnings Ratio20.5621.646351.4643
Very volatile
Operating Cycle14213640.0459
Pretty Stable
Price Book Value Ratio3.762.57664.131
Slightly volatile
Dividend Payout Ratio0.470.49060.9489
Pretty Stable
Price To Operating Cash Flows Ratio8.696.70259.2714
Slightly volatile
Price To Free Cash Flows Ratio8.696.70259.2714
Slightly volatile
Pretax Profit Margin0.730.55680.6028
Pretty Stable
Ebt Per Ebit1.120.84911.0051
Very volatile
Operating Profit Margin0.70.65580.5963
Pretty Stable
Company Equity Multiplier2.133.02932.529
Slightly volatile
Long Term Debt To Capitalization0.590.56960.5474
Pretty Stable
Total Debt To Capitalization0.610.58020.5585
Pretty Stable
Return On Capital Employed0.10.08210.0887
Very volatile
Debt Equity Ratio1.381.3821.2651
Pretty Stable
Ebit Per Revenue0.70.65580.5963
Pretty Stable
Quick Ratio0.920.97297.1681
Slightly volatile
Dividend Paid And Capex Coverage Ratio4.186.58243.809
Slightly volatile
Net Income Per E B T0.750.58220.7063
Slightly volatile
Cash Ratio0.920.97253.8507
Slightly volatile
Cash Conversion Cycle14213640.0459
Pretty Stable
Operating Cash Flow Sales Ratio0.811.04690.9452
Slightly volatile
Days Of Sales Outstanding14213640.0459
Pretty Stable
Cash Flow Coverage Ratios0.250.27820.2646
Slightly volatile
Price To Book Ratio3.762.57664.131
Slightly volatile
Price Cash Flow Ratio8.696.70259.2714
Slightly volatile
Enterprise Value Multiple21.615.296324.6463
Slightly volatile
Debt Ratio0.530.45620.5016
Slightly volatile
Cash Flow To Debt Ratio0.250.27820.2646
Slightly volatile
Price Sales Ratio9.967.017111.2505
Slightly volatile
Return On Assets0.07790.03930.0662
Very volatile
Asset Turnover0.150.12120.1456
Slightly volatile
Net Profit Margin0.540.32420.4533
Very volatile
Price Fair Value3.762.57664.131
Slightly volatile
Return On Equity0.20.1190.1629
Very volatile

Royalty Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.6 B14.2 B15.5 B
Slightly volatile
Enterprise Value16.9 B19.6 B21 B
Slightly volatile

Royalty Fundamental Market Drivers

Forward Price Earnings14.4718
Cash And Short Term Investments637.5 M

Royalty Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue27.9 M24.8 M
Total Revenue2.4 B1.3 B
Cost Of Revenue3.9 M3.7 M
Stock Based Compensation To Revenue 0.12  0.13 
Sales General And Administrative To Revenue 0.24  0.25 
Research And Ddevelopement To Revenue 0.19  0.20 
Revenue Per Share 5.51  3.82 
Ebit Per Revenue 0.66  0.70 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY